Literature DB >> 31268424

Are Patients Who Undergo THA for Infection at Higher Risk for 30-day Complications?

Anthony J Boniello1, Alexander M Lieber, P Maxwell Courtney.   

Abstract

BACKGROUND: Value-based payment models, such as bundled payments, continue to become more widely adopted for total joint arthroplasty. However, concerns exist regarding the lack of risk adjustment in these payment and quality reporting models for THA. Providers who care for patients with more complicated problems may be financially incentivized to screen out such patients if reimbursement models fail to account for increased time and resources needed to care for these more complex patients. QUESTIONS/PURPOSES: (1) Are patients who undergo revision THA for infectious causes at greater adjusted risk of 30-day short-term major complications, return to the operating room, readmission, and mortality compared with patients undergoing aseptic revision? (2) What are other independent factors associated with the risk of 30-day major complications, readmission, and mortality in this patient population?
METHODS: We queried the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database for all patients undergoing revision THA from 2012 to 2015. The NSQIP database allows for the analysis of 30-day surgical outcomes, including postoperative complications, return to the operating room, readmission, and mortality of patients from approximately 400 participating institutions. The NSQIP was selected over other larger databases, such as the National Impatient Sample (NIS), because the NSQIP includes readmission data and 30-day complications rates that were relevant to our study. Patients undergoing aseptic revision THA and those undergoing revision THA with a diagnosis of periprosthetic joint infection were identified. We identified 8973 patients who underwent revision THA and excluded six patients due to a diagnosis of malignancy leaving 8967 patients; 726 (8%) of these were due to infection. Demographic variables, medical comorbidities, and 30-day major complications, hospital readmissions, reoperations, and mortality were compared among patients undergoing aseptic and infected revision THA. A major complication was defined as myocardial infarction, postoperative mortality, sepsis, septic shock, and stroke. A multivariate logistic regression analysis was then performed to identify factors independently associated with the primary outcome of 30-day hospital readmission, and secondary endpoints of 30-day major complications, return to operating room, and mortality.
RESULTS: Controlling for medical comorbidities and demographic factors, the patients who underwent THA for infection were more likely to experience a major complication (odds ratio [OR], 4.637; 95% confidence interval [CI], 2.850-7.544; p < 0.001) within 30 days of surgery and more likely to return to the operating room (OR = 1.548; 95% CI, 1.062-2.255; p = 0.023). However, there were no greater odds of 30-day readmission (OR, 1.354; 95% CI, 0.975-1.880; p = 0.070) or 30-day mortality (OR, 0.661; 95% CI, 0.218-2.003; p = 0.465). Preoperative malnutrition was associated with an increased risk of return to the operating room (OR, 1.561; 95% CI, 1.152-2.115; p = 0.004), 30-day readmission (OR, 1.695; 95% CI, 1.314-2.186; p < 0.001), and 30-day mortality (OR, 7.240; 95% CI, 2.936-17.851; p < 0.001).
CONCLUSIONS: Patients undergoing revision THA for infection undergo reoperation and experience major complications more frequently in a 30-day episode of care than patients undergoing aseptic revision THA. Without risk adjustment to existing alternative payment and quality reporting models, providers may experience a disincentive to care for patients with infected THAs, who may face difficulties with access to care. LEVEL OF EVIDENCE: Level III, therapeutic study.

Entities:  

Mesh:

Year:  2019        PMID: 31268424      PMCID: PMC6999996          DOI: 10.1097/CORR.0000000000000760

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  23 in total

1.  The epidemiology of revision total hip arthroplasty in the United States.

Authors:  Kevin J Bozic; Steven M Kurtz; Edmund Lau; Kevin Ong; Thomas P Vail; Daniel J Berry
Journal:  J Bone Joint Surg Am       Date:  2009-01       Impact factor: 5.284

2.  Strategies and tactics for successful implementation of bundled payments: bundled payment for care improvement at a large, urban, academic medical center.

Authors:  Richard Iorio
Journal:  J Arthroplasty       Date:  2015-01-23       Impact factor: 4.757

3.  What Is the Impact of Smoking on Revision Total Knee Arthroplasty?

Authors:  Nicholas A Bedard; S Blake Dowdle; Brandon G Wilkinson; Kyle R Duchman; Yubo Gao; John J Callaghan
Journal:  J Arthroplasty       Date:  2018-03-17       Impact factor: 4.757

4.  Perioperative Complications and Length of Stay After Revision Total Hip and Knee Arthroplasties: An Analysis of the NSQIP Database.

Authors:  Emmanouil Liodakis; Stephane G Bergeron; David J Zukor; Olga L Huk; Laura M Epure; John Antoniou
Journal:  J Arthroplasty       Date:  2015-05-22       Impact factor: 4.757

5.  Revision hip arthroplasty: infection is the most common cause of failure.

Authors:  S Mehdi Jafari; Catelyn Coyle; S M Javad Mortazavi; Peter F Sharkey; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2010-08       Impact factor: 4.176

6.  Complications After Revision Total Hip Arthroplasty in the Medicare Population.

Authors:  Sameer Badarudeen; Albert C Shu; Kevin L Ong; Doruk Baykal; Edmund Lau; Arthur L Malkani
Journal:  J Arthroplasty       Date:  2017-02-01       Impact factor: 4.757

7.  Risk Adjustment Is Necessary in Value-based Outcomes Models for Infected TKA.

Authors:  P Maxwell Courtney; Anthony J Boniello; Craig J Della Valle; Gwo-Chin Lee
Journal:  Clin Orthop Relat Res       Date:  2018-10       Impact factor: 4.176

8.  Should All Patients Be Included in Alternative Payment Models for Primary Total Hip Arthroplasty and Total Knee Arthroplasty?

Authors:  Joshua C Rozell; Paul M Courtney; Jonathan R Dattilo; Chia H Wu; Gwo-Chin Lee
Journal:  J Arthroplasty       Date:  2016-03-24       Impact factor: 4.757

9.  Medical comorbidities are independent preoperative risk factors for surgical infection after total joint arthroplasty.

Authors:  Joshua S Everhart; Eric Altneu; Jason H Calhoun
Journal:  Clin Orthop Relat Res       Date:  2013-10       Impact factor: 4.176

10.  Spinal surgery: variations in health care costs and implications for episode-based bundled payments.

Authors:  Beatrice Ugiliweneza; Maiying Kong; Kristin Nosova; Kevin T Huang; Ranjith Babu; Shivanand P Lad; Maxwell Boakye
Journal:  Spine (Phila Pa 1976)       Date:  2014-07-01       Impact factor: 3.468

View more
  5 in total

1.  Editorial Comment: 2018 Musculoskeletal Infection Society Proceedings.

Authors:  Antonia F Chen; Charalampos G Zalavras
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

2.  CORR Insights®: Are Patients Who Undergo THA for Infection at Higher Risk for 30-day Complications?

Authors:  Charalampos G Zalavras
Journal:  Clin Orthop Relat Res       Date:  2019-08       Impact factor: 4.176

3.  Editorial Comment: 2019 Musculoskeletal Infection Society Proceedings.

Authors:  Charalampos G Zalavras; Barry D Brause
Journal:  Clin Orthop Relat Res       Date:  2020-08       Impact factor: 4.755

4.  Revision Total Hip Arthroplasty in Solid Organ Transplant Patients: A Propensity Score-Matched Cohort Study for Aseptic and Infected Revisions.

Authors:  Alex Upfill-Brown; Christopher M Hart; Peter P Hsiue; Kadarius Burgess; Clark J Chen; Amir Khoshbin; Christos Photopoulos; Alexandra I Stavrakis
Journal:  Arthroplast Today       Date:  2022-01-20

5.  Microbiology of Periprosthetic Hip and Knee Infections in Surgically Revised Cases from 34 Centers in Mainland China.

Authors:  Hui-Ming Peng; Zong-Ke Zhou; Fei Wang; Shi-Gui Yan; Peng Xu; Xi-Fu Shang; Jia Zheng; Qing-Sheng Zhu; Li Cao; Xi-Sheng Weng
Journal:  Infect Drug Resist       Date:  2021-06-25       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.